<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081494</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001I2102</org_study_id>
    <secondary_id>2017-000466-30</secondary_id>
    <nct_id>NCT03081494</nct_id>
  </id_info>
  <brief_title>Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ib study of PDR001 in combination with regorafenib in adult patients with
      previously treated metastatic microsatellite stable (MSS) colorectal cancer. The study will
      assess primarily the safety and tolerability and then the efficacy of PDR001 in combination
      with regorafenib. Particular attention will be paid to the level of activity of study drug
      combinations in CMS4 patients (retrospective analysis).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 1b study, dose escalation (N=~12) followed with an expansion (N=~60). One single arm: PDR001 in combination with regorafenib</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose-limiting toxicity (DLT)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) per investigator assessment using RECIST v1.1</measure>
    <time_frame>23 months</time_frame>
    <description>RECIST v1.1 = Response Evaluation Criteria in Solid Tumors v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) per central assessment using RECIST v1.1</measure>
    <time_frame>Baseline, every 8 weeks until progression per central assessment up to 1 year after last patient last visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Every 3 months after last visit up to 1 year after last patient first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Baseline, every 8 weeks until progression up to 1 year after last patient last visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Baseline, every 8 weeks until progression up to 1 year after last patient last visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Baseline, every 8 weeks until progression up to 1 year after last patient last visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 3 Day 21, Cycle 4 Day 1, Cycle 4 Day 21, Cycle 6 Day 1, Cycle 6 Day 21, Cycle 8 Day 21, Cycle 12 Day 1 and then every 6 cycles until end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 3 Day 21, Cycle 4 Day 1, Cycle 4 Day 21, Cycle 6 Day 1, Cycle 6 Day 21, Cycle 8 Day 21, Cycle 12 Day 1 and then every 6 cycles until end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 3 Day 21, Cycle 4 Day 1, Cycle 4 Day 21, Cycle 6 Day 1, Cycle 6 Day 21, Cycle 8 Day 21, Cycle 12 Day 1 and then every 6 cycles until end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADA)</measure>
    <time_frame>Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 8 Day 1, Cycle 10 Day 1, Cycle 12 Day 1, and then every 6 cycles until end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>400 mg every 4 weeks</description>
    <arm_group_label>PDR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>regorafenib</intervention_name>
    <description>either 160 or 120 or 80 mg once daily first 21 days of each 28-day cycle (=4 weeks)</description>
    <arm_group_label>PDR001</arm_group_label>
    <other_name>StivargaÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:

          1. Patients with metastatic colorectal adenocarcinoma.

          2. Patients must provide a newly obtained or an archival tumor sample corresponding to
             CRC diagnosis (primary tumor) with sufficient tissue quality (qualified) for analysis

          3. Patients must provide a newly obtained tumor tissue sample from a metastatic site

          4. Patients with the presence of at least one lesion with measurable disease as per
             RECIST

          5. Patients previously treated with two prior regimen as per standard of care and have
             experienced disease progression (including -VEGF and EGFR targeted therapies (if KRAS
             wild).

          6. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-1

        Key exclusion criteria:

          1. Patients with MSI-H colorectal adenocarcinoma as defined per local assessment using
             standard of care testing

          2. Patients with metastatic disease amenable to be resected with potentially curative
             surgery

          3. Patients who have had chemotherapy, radiation, or biological cancer therapy within 14
             days prior to the first dose of study treatment

          4. Patients with a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PDL2,
             anti- CTLA-4 antibodies, other checkpoint inhibitors

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2017</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDR001</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>regorafenib</keyword>
  <keyword>CRC</keyword>
  <keyword>MMS</keyword>
  <keyword>CMS4</keyword>
  <keyword>ElevatION:CRC-102</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

